Nora Scanlan
A5003253691- Lymphoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Galectins and Cancer Biology
- CAR-T cell therapy research
- Immune Cell Function and Interaction
Massachusetts General Hospital
2022-2024
Abstract Purpose: Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms. Experimental Design: Primary specimens, cell lines, patient-derived xenograft models, commercially available, proprietary anti-KLRG1 antibodies were used screening, target, functional validation. Results: Here we demonstrate that surface KLRG1 is highly expressed on tumor cells in subsets extranodal NK/T-cell lymphoma (ENKTCL), T-prolymphocytic leukemia (T-PLL),...
<p>Supplementary Methods and Figures</p>
<p>Supplementary Methods and Figures</p>
<div>AbstractPurpose:<p>Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms.</p>Experimental Design:<p>Primary specimens, cell lines, patient-derived xenograft models, commercially available, proprietary anti-KLRG1 antibodies were used screening, target, functional validation.</p>Results:<p>Here we demonstrate that surface KLRG1 is highly expressed on tumor cells in subsets extranodal NK/T-cell lymphoma...
<div>AbstractPurpose:<p>Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms.</p>Experimental Design:<p>Primary specimens, cell lines, patient-derived xenograft models, commercially available, proprietary anti-KLRG1 antibodies were used screening, target, functional validation.</p>Results:<p>Here we demonstrate that surface KLRG1 is highly expressed on tumor cells in subsets extranodal NK/T-cell lymphoma...